Wisłowska M, Jabłońska B
Department of Rheumatology, Central Clinical Hospital, Woloska 137, 02-507, Warsaw, Poland.
Clin Rheumatol. 2005 Jun;24(3):278-84. doi: 10.1007/s10067-004-1000-x. Epub 2004 Nov 18.
The cartilage oligometrix matrix protein (COMP) is a noncollagenous protein, a glycoprotein, the function of which is to bind to type II collagen fibres and stabilise the collagen fibre network in the articular cartilage. In the serum of the normal population the COMP level is 5 mug/ml. An increased level of COMP in the synovial fluid was described in the early stage of rheumatoid arthritis (RA), whereas in advanced stages of RA, the level of COMP decreased. In this study we assessed the serum COMP level in patients with RA and knee osteoarthritis (OA) and found a correlation between the serum COMP level and other markers as well as bone mass density (BMD) changes, activity of disease, disease duration and the age of the patients. The blood was collected from 30 RA patients and 30 OA patients who constituted the control group. The serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay (ELISA). The average value of the serum COMP level in RA patients was 10.4+/-3.6 U/l. There was a correlation between the serum COMP level and the age of RA patients (p<0.005) and disease activity score (DAS) value (p<0.01). According to correlation coefficients, the serum COMP level was independent of stage of disease, number of painful and swollen joints, duration of morning stiffness, disease duration and titre of the Waaler-Rose test. The influence of rheumatoid nodule presence on the serum COMP level was shown (p<0.05). In RA patients with erythrocyte sedimentation rate (ESR) values below 20 mm/h compared with patients with ESR values over 60 mm/h, the serum COMP level was observed to be significantly lower (p<0.05). The average value of COMP in OA patients was 10.4+/-2.7 U/l. No correlation was found between the serum COMP level and patients' age and disease duration. There was a correlation between the serum COMP level and Western Ontario and McMaster Universities (WOMAC) index pain scale for the lower limbs (p<0.005) and T-score value of densitometry examinations (p<0.036) in OA patients. No statistical differences were found between the average serum COMP level in RA and OA patients.
软骨寡聚基质蛋白（COMP）是一种非胶原蛋白，属于糖蛋白，其功能是与II型胶原纤维结合并稳定关节软骨中的胶原纤维网络。在正常人群血清中，COMP水平为5微克/毫升。类风湿关节炎（RA）早期滑膜液中COMP水平升高，而在RA晚期，COMP水平下降。在本研究中，我们评估了RA患者和膝骨关节炎（OA）患者的血清COMP水平，发现血清COMP水平与其他标志物以及骨密度（BMD）变化、疾病活动度、病程和患者年龄之间存在相关性。从30例RA患者和30例作为对照组的OA患者中采集血液。使用抑制酶联免疫吸附测定（ELISA）法测定血清COMP水平。RA患者血清COMP水平的平均值为10.4±3.6 U/l。血清COMP水平与RA患者年龄（p<0.005）和疾病活动评分（DAS）值（p<0.01）之间存在相关性。根据相关系数，血清COMP水平与疾病分期、疼痛和肿胀关节数量、晨僵持续时间、病程以及瓦勒-罗斯试验滴度无关。显示了类风湿结节的存在对血清COMP水平的影响（p<0.05）。与红细胞沉降率（ESR）值超过60毫米/小时的患者相比，ESR值低于20毫米/小时的RA患者血清COMP水平明显较低（p<0.05）。OA患者COMP的平均值为10.4±2.7 U/l。未发现血清COMP水平与患者年龄和病程之间存在相关性。OA患者血清COMP水平与下肢西安大略和麦克马斯特大学（WOMAC）指数疼痛量表（p<0.005）以及骨密度检查的T值（p<0.036）之间存在相关性。RA患者和OA患者的平均血清COMP水平之间未发现统计学差异。
